gefitinib has been researched along with geranylgeranyl pyrophosphate in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (geranylgeranyl pyrophosphate) | Trials (geranylgeranyl pyrophosphate) | Recent Studies (post-2010) (geranylgeranyl pyrophosphate) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 518 | 3 | 203 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bi, F; Bi, NX; Gong, QY; Liu, BS; Liu, Q; Nie, YZ; Tang, QL; Xia, HW; Zhou, JT; Zhou, S | 1 |
1 other study(ies) available for gefitinib and geranylgeranyl pyrophosphate
| Article | Year |
|---|---|
Inhibition of YAP reverses primary resistance to EGFR inhibitors in colorectal cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Anticholesteremic Agents; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphoproteins; Polyisoprenyl Phosphates; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Simvastatin; Transcription Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2018 |